Pricing Log in Create free account
Friday 6 November 2026 Export UTHR’s income statement to Excel — free account

United Therapeutics Corporation

UTHR Healthcare Drug Manufacturers Specialty & Generic

United Therapeutics Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 10.6% from fiscal 2024.

Revenue
+4.13%
EPS
−21.7%
Free cash flow
−63.7%

Quarter to September 2026, against a year earlier

564.88 43.61 −7.17%
Market cap
$24.3B
P/E
19.7×
Fwd P/E
22.5×
Dividend yield
—
F-score
8/9
Altman Z
19.55
Beneish M
−2.26
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

United Therapeutics Corporation (UTHR) SEC filings, changes and red flags

Red flags

Filings

Form Period Filed What it reports Flags
8-K Nov 4, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Sep 30, 2026 P1I2: 20 added · 10 removed · 51 modified
P2I1A: 1 added · 44 modified
8-K Oct 21, 2026 8.01 Other events; 9.01 Financial statements and exhibits
8-K Oct 13, 2026 8.01 Other events; 9.01 Financial statements and exhibits
8-K Sep 8, 2026 1.01 Entry into a material definitive agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Aug 5, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2026 P1I2: 17 added · 5 removed · 41 modified
P2I1A: 2 added · 2 removed · 41 modified
8-K Jul 22, 2026 5.02 Departure or appointment of directors or officers; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits Officer departure
8-K Jun 26, 2026 5.02 Departure or appointment of directors or officers; 5.07 Submission of matters to a vote of security holders; 9.01 Financial statements and exhibits
8-K May 6, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Mar 31, 2026
8-K Mar 30, 2026 8.01 Other events; 9.01 Financial statements and exhibits
8-K Mar 9, 2026 1.01 Entry into a material definitive agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Mar 2, 2026 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Feb 25, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-K Dec 31, 2025 1: 28 added · 48 removed · 128 modified
1A: 7 added · 4 removed · 61 modified
7: 6 added · 11 removed · 46 modified
8-K Jan 21, 2026 5.02 Departure or appointment of directors or officers; 5.03 Amendments to the articles or bylaws; change in fiscal year; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Oct 29, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Sep 30, 2025
8-K Sep 2, 2025 8.01 Other events; 9.01 Financial statements and exhibits
8-K Jul 30, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2025
8-K Apr 30, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Mar 31, 2025
8-K Feb 26, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-K Dec 31, 2024
8-K Oct 30, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Sep 30, 2024
8-K Jul 31, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2024
8-K May 1, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Feb 21, 2024 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.